Three signal classes are central: soluble factors, extracellular vesicles, and cytokines. Released by the primary tumor, they travel through the circulation and communicate with distant tissues before cancer cells arrive. Their coordinated effects help recruit bone marrow-derived cells and initiate local remodeling, making the tissue more receptive to later metastatic colonization.
Bone marrow-derived cells are not merely bystanders in this process. Signals from the primary tumor recruit them to distant tissues, where their presence contributes to the local changes associated with future colonization. Tracking this recruitment links a tumor’s systemic communication with measurable alterations in a target organ, helping researchers identify early events in dissemination.
Organ preference can reflect differences in how distant tissues respond to tumor-derived signals. Changes to the extracellular matrix can modify the local environment, while altered immune activity may make the tissue more supportive of arriving cancer cells. Examining both features helps explain why metastatic spread is not uniform across organs and why some sites become favored targets.
Researchers can connect events in the primary tumor with changes in distant organs before cancer cells appear there. Key observations include circulating soluble factors, extracellular vesicles, and cytokines, followed by bone marrow-derived cell recruitment, extracellular matrix remodeling, and immune alterations in candidate target tissues. This timeline helps distinguish preparation from later colonization.
Pre-metastatic niche research can support biomarkers that estimate metastatic risk. Such markers would be based on early signals or tissue changes associated with niche formation, rather than only on established secondary tumors. Their value lies in identifying dissemination-related risk before metastatic growth is fully evident, supporting research focused on earlier intervention.
Therapeutic strategies can target the tissue-conditioning phase rather than waiting for secondary tumors to grow. Two broad aims are to prevent the relevant distant-tissue changes or disrupt them after they begin. By addressing tumor-derived signals, recruited cells, matrix remodeling, or altered immune activity, researchers seek to reduce conditions that support successful metastatic growth.